Compare Quest Diagnostics Inc (DGX) vs Roundhill NVDA WeeklyPay ETF (NVDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Roundhill NVDA WeeklyPay ETF — how do they compare? Quest Diagnostics Inc trades at $204.8 (market cap $22.80B), while Roundhill NVDA WeeklyPay ETF trades at $37. The key difference: Quest Diagnostics Inc pays a 1.67% dividend while Roundhill NVDA WeeklyPay ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, Roundhill NVDA WeeklyPay ETF nearer its low. Which is the better fit depends on your goals.
| DGX | NVDW | |
|---|---|---|
Market Cap | $22.80B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $216.02 | $53.42 |
52-Week Low | $166.42 | $31.88 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
NVDW trades at $35.81, down 4.66% over the past day, with technical indicators showing mixed signals—bullish oscillators but bearish moving averages. The stock has a history of frequent dividend payments, with recent payouts ranging from $0.21 to $0.48 per share. Key support is near $35, while resistance levels start at $38.
The outlook hinges on NVDW's ability to maintain its dividend stream amid market volatility. Risks include dependency on underlying asset performance and payout fluctuations. Upside potential exists if technical resistance is broken, but investors should monitor earnings stability and broader market trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Roundhill NVDA WeeklyPay ETF
NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.
Read more on NVDW →
